Posted by Michael Wonder on 03 Mar 2026
Xpovio receives reimbursement approval in South Korea for a second multiple myeloma indication
1 March 2026 - Antengene announced that South Korea's National Health Insurance Service has approved the reimbursement of Xpovio (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma after one prior therapy.
The reimbursement has taken effect on 1 March 2026. This marks the second Xpovio indication to be approved for reimbursement in South Korea.
